An emerging biotechnology leader for the early diagnosis of sepsis, Trilinear Bioventures is changing today’s standard of patient care. Our novel platform quickly and non-invasively detects a patient’s risk of sepsis and continuously monitors infection status and response to treatment.
Our disruptive integration of state-of-the-art optical biosensor technology, cutting-edge advancements in microvascular science, and exploding growth of big data applications is supported by more than five years of research and development by a Fortune 500 international technology manufacturer, renown medical experts, and a portfolio of over 25 U.S. patents.
Trilinear is delivering an indispensable front-line diagnostic and patient monitoring solution that will revolutionize the next generation of personalized medicine.
Trilinear BioVentures, LLC™
Visit us on the campus of HudsonAlpha Institute for Biotechnology